15 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 18 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 15, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow lofexidine: new trials by email Literature Review of lofexidine trials Research Report on lofexidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects LUCEMYRA (lofexidine) tablets - Opioid Withdrawal (Disorder), Opioid Use Disorder | Phase 1 | Withdrawn | USWM, LLC (dba US WorldMeds) | 2025-06-01 | 2025-08-01 | |
| Sublingual Dexmedetomidine for Treating Opioid Withdrawal BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Active not recruiting | New York State Psychiatric Institute | 160 | 2023-02-28 | 2026-10-28 |
| A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution Lofexidine (granules for reconstitution), LUCEMYRA (lofexidine) tablets - Normal Healthy Volunteers | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 16 | 2021-02-16 | 2022-06-15 |
| Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers Lofexidine, Paroxetine - Healthy | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 24 | 2016-01-01 | 2018-02-23 |
| Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects Lofexidine + Naltrexone - Healthy | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 25 | 2015-05-01 | 2017-10-26 |
| Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects lofexidine HCl - Renally Impaired Subjects | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 16 | 2014-11-01 | 2017-10-26 |
| Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects Lofexidine Hydrochloride (HCl) tablets - Liver Failure | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 24 | 2014-06-01 | 2018-02-23 |
| Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients Lofexidine HCl, Lofexidine-matching sugar pill - Opioid Dependence, Buprenorphine Withdrawal Syndrome | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 30 | 2013-03-01 | 2018-02-23 |
| Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients Lofexidine HCl, Lofexidine-matching sugar pill - Opioid Dependence, Methadone Withdrawal Syndrome | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 27 | 2012-07-01 | 2017-10-26 |
| Lofexidine Mass Balance in Volunteers Lofexidine hydrochloride - Normal Healthy Volunteers | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 6 | 2012-05-01 | 2017-10-26 |
| Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients Lofexidine HCl - Opioid Dependence, Methadone Withdrawal Syndrome | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 6 | 2012-02-01 | 2018-02-23 |
| Lofexidine Food Effect Study in Healthy Volunteers Lofexidine HCl - Healthy | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 13 | 2011-10-01 | 2018-02-23 |
| Lofexidine ADME & Mass Balance in Volunteers Lofexidine hydrochloride - Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 12 | 2011-07-01 | 2017-10-26 |
| Interactions Between Intravenous (IV) Cocaine and Lofexidine Lofexidine, Placebo - Cocaine Related Disorders | Phase 1 | Terminated | National Institute on Drug Abuse (NIDA) | 16 | 2010-08-01 | 2017-01-11 |
| Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1 Lofexidine - Heroin Dependence | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 2003-03-01 | 2017-01-12 | |
| Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3 Lofexidine - Opioid-Related Disorders, Substance-Related Disorders | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 1996-07-01 | 2017-01-12 | |
| Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10 Lofexidine - Opioid-Related Disorders | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 1996-04-01 | 2017-01-12 | |
| Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7 Lofexidine - Opioid-Related Disorders, Substance-Related Disorders | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 2017-01-12 |
Opioid-Related Disorders (8) · Substance-Related Disorders (2) · Cocaine-Related Disorders (1) · Heroin Dependence (1) · Kidney Failure, Chronic (1) · Liver Failure (1)
USWM, LLC (dba US WorldMeds) (12) · National Institute on Drug Abuse (NIDA) (5) · New York State Psychiatric Institute (1)
United States (18)
James A Longstreth, PhD (6) · Charles W Gorodetzky, MD, PhD (5) · Charles O'Brien, M.D., Ph.D. (2) · James Longstreth, PhD (2) · Mark Leibowitz, MD (2) · Thomas Marbury, MD (2) · Charles Gorodetzky, MD (1) · Charles Gorodetzky, MD, PhD (1) · Charles W. Gorodetzky, MD, PhD (1) · George Atiee, MD (1) · George J Atiee, MD (1) · Kim New (1) · Sandra Comer, Ph.D (1) · Thomas R Kosten, M.D. (1) · Walter Ling, M.D. (1)
U01DA030916 (3), 1UG3DA061620 (1), R01DA047690 (1), U01DA033276 (1), UG3DA056247-01 (1)